Scientia Vascular, a West Valley City neurovascular medical devices provider, has announced that Rick Randall will replace founder John Lippert as CEO of the company. Lippert will transition to chief technology officer, focusing on advancing next-generation patient solutions and therapies.
Randall has over 35 years in the medical device industry leading neuro-focused organizations, including guiding companies through public offerings and overseeing mergers and acquisitions. His background encompasses strategic planning, product marketing and commercialization of minimally invasive therapeutic products. He served as CEO of Target Therapeutics, where he was pivotal in bringing the neuro-interventional company public and developing pioneering technologies.
“Rick’s leadership will be instrumental in expanding our sales efforts and leading our new marketing team,” said Lippert. “His expertise in commercialization will be invaluable as we bring new products to market, allowing me to concentrate on driving innovation as CTO. Together with our experienced executive team, we anticipate a bright future dedicated to bettering patient outcomes while building a thriving business.”
“Scientia’s next-generation vascular access technology is perfectly suited to the demands of the rapidly growing interventional stroke treatment landscape,” said Randall. “I look forward to working with the Scientia team as we continue to redefine the way the neurovascular system is accessed and cerebral disease states are treated.”
“This leadership transition positions Scientia Vascular to continue its trajectory of innovation and growth, reinforcing its commitment to developing advanced medical devices that improve patient care in the neurovascular space,” a Scientia statement said.
